| dexamethasone / Generic mfg. |
ChiCTR-TRC-13003354: Multicenter, randomized, open-label and parallel-group clinical study on the efficacy and safety of arsenic plus vitamin C combined with chemotherapy for treating relapsed and refractory B-cell non-Hodgkin lymphoma |
|
|
| Completed | 2 | 520 | | Regimen of DICE: Ifosfomide (1000mg/m2/day), carboplatin(120mg/m2/day) , etoposide (120mg/m2 /day), and dexamethasone (40mg/day) are injected from day 1 through day 4, and G-CSF (0.5μg/kg/day) is subcutaneously injected from day 5 through day 12. ;Regimen of DHAP：Carboplatin (120mg/m2/day) is injected from day 1 through day 3, and dexamethasone (40mg/day) from day 1 through day4, and cytarabine at a dosage of 2000mg/m2 is injected twice a day at the second day. ;Arsenic trioxide plus VitC combined with DICE regimen: Arsenic trioxide (0.16mg/kg/d) plus Vit C (1000mg/day) are injected from day1 through day 14. Regimen of DICE: Ifosfomide (1000mg/m2/day), carboplatin(120mg/m2/day) , etoposide (120mg/m2 /day), and dexamethasone (40mg/day) are injected from day 1 through day 4, and G-CSF (0.5μg/kg/day) is subcutaneously injected from day 5 through day 12. (DICE regimen is initiated from the eighth day of usage of arsenic trioxide). ;Arsenic trioxide plus VitC combined with DHAP regimen: Arsenic trioxide (0.16mg/kg/d) plus Vit C (1000mg/day) are injected from day1 through day 14. Regimen of DHAP：Carboplatin (120mg/m2/day) is injected from day 1 through day 3, and dexamethasone (40mg/day) from day 1 through day4, and cytarabine at a dosage of 2000mg/m2 is injected twice a day at the second day.(DHAP regimen is initiated from the eighth day of usage of arsenic trioxide). | Department of Hematology, the Second Affiliated Hospital of Dalian Medical University.; Department of Hematology, the Second Affiliated Hospital of Dalian Medical University., LiaoNing Project for Medicine Peak Construction (No.201112;2011-2013). 200,000 Yuan. | Non-Hodgkin lymphoma (B-cell) | | | | |
NCT00003663: Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma |
|
|
| Withdrawn | 2 | 0 | US | rituximab, dexamethasone | Hoag Memorial Hospital Presbyterian, Cancer Biotherapy Research Group | Lymphoma | 01/00 | 01/00 | | |
NCT00002691: Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | | US | filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mesna, methotrexate, vincristine sulfate | Memorial Sloan Kettering Cancer Center | Lymphoma | 06/00 | 06/00 | | |
NCT00003416: S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia |
|
|
| Completed | 2 | 9 | US | filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation | Southwest Oncology Group, National Cancer Institute (NCI) | Lymphoma | 08/00 | 01/04 | | |
NCT00074191: Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma |
|
|
| Completed | 2 | 1 | US | cytarabine, dexamethasone, lomustine, methotrexate, procarbazine hydrochloride | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Lymphoma | 10/00 | 10/00 | | |
NCT00014209: Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment |
|
|
| Completed | 2 | 77 | Canada | cisplatin, dexamethasone, gemcitabine hydrochloride | NCIC Clinical Trials Group, Eli Lilly and Company | Lymphoma | 07/02 | 02/09 | | |
NCT00002471: Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | | US | asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, methotrexate, methylprednisolone, therapeutic hydrocortisone, thiotepa, vincristine sulfate | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphoma | 01/03 | 01/03 | | |
NCT00003278: Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 28 | US, Canada | dexamethasone, radiation therapy | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Lymphoma | 06/03 | 06/03 | | |
NCT00005601: Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 58 | US, Canada | rituximab, cisplatin, cytarabine, dexamethasone, sargramostim | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Lymphoma | 07/03 | 02/08 | | |
NCT00006345: Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma |
|
|
| Completed | 2 | | US | denileukin diftitox, dexamethasone | Ligand Pharmaceuticals | Drug/Agent Toxicity by Tissue/Organ, Lymphoma | | 03/04 | | |
NCT00491127: Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 10 | Europe | gemcitabine, cisplatin, dexamethasone | Eli Lilly and Company | Non-Hodgkin's Lymphoma | | 06/04 | | |
NCT00090909: Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma |
|
|
| Completed | 2 | 1 | US | cisplatin, dexamethasone, gemcitabine hydrochloride | Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI) | Lymphoma | 03/05 | | | |
NCT00285389: Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years |
|
|
| Completed | 2 | 39 | Europe | Adriblastin, dexamethasone, Chlorambucil, rituximab, cyclophosphamide, alkeran, Total body irradiation (8Gy/4fr), vincristine | French Innovative Leukemia Organisation, Hoffmann-La Roche | Mantle Cell Lymphoma | 12/05 | 12/08 | | |
NCT00556127: Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma |
|
|
| Completed | 2 | 94 | Europe | Rituximab, Epirubicin, Cyclophosphamide, Vincristine, Prednisone, Granulocyte-colony-stimulating factor, Mitoxantrone, Cytarabine ARA-C, Dexamethasone, Carmustine BCNU, Etoposide, Melphalan, Radiotherapy, PBSC reinfusion | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Diffuse Large B-Cell Lymphoma, POOR PROGNOSIS | | 09/06 | | |
| Unknown status | 2 | 16 | Europe | bortezomib, rituximab, dexamethasone, treatment protocol | Medical University of Vienna | Lymphoma, Mantle-Cell | | 01/07 | | |
NCT00148018: Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma |
|
|
| Terminated | 2 | 37 | Europe | Bortezomib, Dexamethasone | University of Cologne, German Hodgkin's Lymphoma Study Group, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Hodgkin Disease | | | | |
NCT00418535: Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma |
|
|
| Completed | 2 | | RoW | Concurrent Radiotherapy (RT)/cisplatin, VIPD | Samsung Medical Center, Korea University Anam Hospital, Asan Medical Center, Gyeongsang National University Hospital | Lymphoma, T-Cell | 03/09 | 07/09 | | |
NCT00561301: Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma |
|
|
| Unknown status | 2 | 43 | RoW | GemDOx | Cooperative Study Group A for Hematology | Lymphoma | | 10/09 | | |
FAD, NCT00840385: Orally Fludarabine, Adriamycin and Dexamethasone () in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) |
|
|
| Unknown status | 2 | 30 | RoW | FAD, Fludarabine phosphate, oral fludarabine | Fudan University | T-Cell Lymphomas, Chemotherapy | 11/10 | 11/10 | | |
NCT00568607: Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma |
|
|
| Unknown status | 2 | 60 | RoW | IFO, VP-16, DDP, DXM, DICE | Fudan University | Lymphoma | 12/10 | 12/10 | | |
| Completed | 2 | 39 | Europe | rituximab, Mabthera ®,, bortezomib, Velcade, dexamethasone, Bendamustine, Levact ® | French Innovative Leukemia Organisation, Janssen, LP, Mundipharma Pte Ltd. | Lymphoma | 05/11 | 08/15 | | |
NCT00823719: Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) |
|
|
| Completed | 2 | 61 | US | ofatumumab + ICE, ofatumumab + DHAP | GlaxoSmithKline | Lymphoma, Large-Cell, Diffuse | 07/11 | 09/11 | | |
|
|
Cll2O, NCT01392079 / 2007-003099-20: Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine |
|
|
| Completed | 2 | 135 | Europe | Alemtuzumab | University of Ulm, Technische Universität München, WiSP Wissenschaftlicher Service Pharma GmbH, German CLL Study Group | Chronic Lymphocytic Leukemia | 01/12 | 03/16 | | |
NCT00836173: Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Withdrawn | 2 | 0 | US | RICE, GaRD Treatment | Loyola University, Genta Incorporated | Diffuse Large B-cell Lymphoma | 05/12 | 05/12 | | |
NCT00933673: New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma |
|
|
| Unknown status | 2 | 76 | RoW | L-asp, DXM, IFO, VP-16, DDP, L-DICE | Fudan University | Lymphoma | 06/12 | 06/12 | | |
| Completed | 2 | 10 | Europe | Lenalidomide plus dexamethasone, Revlimid ®, 25mg | Institut de Cancérologie de la Loire, Celgene Corporation | Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 07/12 | 08/13 | | |
LVDP-NKT, ChiCTR-TNC-12002353: L-asparaginase, cisplatin, Etoposide and Dexamethasone (LVDP) protocol in combination with radiotherapy for patinets with newly diagnosed NK/T cell lymphoma |
|
|
| Completed | 2 | 60 | | chemotherapy and radiotherapy ;chemotherapy and radiotherapy | Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University; West China Hospital of Sichuan University, Self funding | Extranodal NK/T cell lymphoma, nasal type | | | | |
| Completed | 2 | 100 | Europe | Etoposide, Cyclophosphamide, Doxorubicin, Prednisone, Procarbazine, Dexamethasone, Dacarbazine, Brentuximab Vedotin | University of Cologne, Millennium Pharmaceuticals, Inc. | Hodgkin Lymphoma | 03/14 | 12/17 | | |
2014-001620-29: Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy. Ensayo clínico para evaluar el tratamiento con un medicamento (lenalidomida) añadido a la quimioterapia utilizada habitualmente en pacientes con linfoma difuso de células grandes B (cáncer de la sangre) que no han respondido bien a tratamientos previos y que no pueden recibir quimioterapia a altas dosis |
|
|
| Ongoing | 2 | 77 | Europe | Lenalidomide, Rituximab, Gemcitabine, Cisplatin, NA, Capsule, hard, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Revlimid 5 mg, MabThera, Revlimid 10 mg, Revlimid 15 mg | Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL), Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL) | Refractory Diffuse large B-cell lymphoma. Linfoma difuso de células grandes B refractarios., Sort of cancer (Large B cells lymphoma) from specific haematological cells (from the blood). Tipo de cáncer (Linfoma de cálulas B grandes) que afecta a determinadas células hematológicas (de la sangre), Diseases [C] - Cancer [C04] | | | | |
NCT01238159: Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma |
|
|
| Completed | 2 | 30 | RoW | CCRT+MIDLE chemotherapy, Chemoradiotherapy | Samsung Medical Center, Asan Medical Center, Yonsei University, Seoul National University, Chonnam National University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | 12/14 | 12/14 | | |
ChiCTR-TNC-10000782: Gemcitabine, L-asparaginase, Isophosphomide, Dexamethasone and Etoposide (GLIDE) In Patients with Newly Diagnosed Stage III/IV and Recurrent or Refractory Aggressive NK/T Cell Lymphoma |
|
|
| Completed | 2 | 10 | | Gemcitabine 800mg/m^2 Day1, 8; L-ASP 6000mg/m^2 Day 8, 10, 12, 14, 16, 18, 20; isophosphomide 1g/m^2 Day 1-3; Dexamethasone 40mg Day 1-4, Day 9-12 (prednisone 100mg Day 1-5 for first cyle of gastrointestianl lymphoma); etopside 100mg//m^2 Day 1-3. 6 to 8 cycles in total | West China Hospital; Level of the institution：, Self funding | aggressive NK/T cell lymphoma (Extranodal NK/T cell lymphoma, nasal type; aggressive NK/T cell leukemia) | | | | |
| Completed | 2 | 30 | | methotrexate, etoposide, dexamethasone, Polyehylene glycol asparaginase | Department of Hematology, First Affiliated Hospitals (Xijing Hospital)，Fourth Military Medical University; Level of the institution：, Self-financing | extranodal NK/T cell lymphoma | | | | |
NCT01310101: Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 33 | Europe | ofatumumab plus dexamethasone | Brno University Hospital, University Hospital Hradec Kralove, Faculty Hospital Kralovske Vinohrady, General Teaching Hospital, Prague | Chronic Lymphocytic Leukemia | 02/15 | 02/15 | | |
2006-002141-37: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation |
|
|
| Ongoing | 2 | 32 | Europe | dexamethasone, cisplatin, cytarabine, Mabthera, Mabthera | HOVON foundation | relapsed B cell lymphoma | | | | |
2011-001557-85: Intensive induction treatment with B-cell antibody (rituximab), chemotherapy (Ara-C) and steroids (dexamethasone) followed by high dose chemotherapy and autologous transplantation in aggressive mantle cell lymphoma patients younger than 66 years. |
|
|
| | 2 | 15 | Europe | Mabthera, Cytarabine, Dexacortal, Mabthera, Cytarabine, Dexacortal | Nordic Lymphoma Group, Nordic Lymphoma Group | Mantle cell lymphoma | | | | |
2011-004039-30: Intensive induction treatment with antibody therapy (Rituximab), chemotherapy (Ara-C) and steroids (dexamethasone) and bone marrow transplant in aggressive mantle cell lymphoma patients younger that 66 years. |
|
|
| | 2 | 60 | Europe | Mabthera, Cytarabine, Dexamethasone, Mabthera, Cytarabine, Mabthera, Cytarabine | PLymouth Hospitals NHS Trust, CTAAC, Roche, Chugai | Mantle Cell Lymphoma | | 10/12 | | |
NCT01459211 / 2010-024520-15: Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Completed | 2 | 12 | Europe | Lenalidomide & Dexamethasone, Revlimid | University College, London | Chronic Lymphocytic Leukemia | 02/16 | 02/16 | | |
NCT02825147: Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma |
|
|
| Completed | 2 | 40 | RoW | Pegaspargase, Methotrexate, Dexamethasone, Etoposide, radiotherapy | Ruijin Hospital | Nasal Type Extranodal NK/T-Cell Lymphoma | 03/16 | 07/17 | | |
2007-005487-28: Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CLL |
|
|
| Ongoing | 2 | 40 | Europe | dexamethasone, cisplatin, Cytarabine, Mabthera, Mabthera | HOVON Foundation, HOVON, Roche, | Chronic lymphocytic leukemia | | | | |
2010-020868-38: (A Phase 2) STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (Rd) FOLLOWED BY RITUXIMAB, AUTOGRAFT AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED WALDESTROM MACROGLOBULINEMIA SUBJECTS |
|
|
| | 2 | 26 | Europe | REVLIMID, REVLIMID | U.O.C. EMATOLOGIA - OSP. S. EUGENIO - ASL RM C | Waldenstr�m, s Macroglobulinemia | | | | |
2008-000044-14: SALVAGE TREATMENT WITH LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) |
|
|
| Completed | 2 | 33 | Europe | SOLDESAM*OS GTT 10ML 0,2%, SOLDESAM*OS GTT 10ML 0,2% | IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | Treatment of patients with MCL relapsed or refractory to at least one line of chemotherapy, not eligible for or relapsed after more intensive treatments. | | | | |
2010-022681-27: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia |
|
|
| Ongoing | 2 | 30 | Europe | ofatumumab, Arzerra, | University Hospital Brno | Patients with refractory/relapsed CLL | | | | |
2010-019575-29: Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210) |
|
|
| | 2 | 66 | Europe | Dexamethasone, Ofatumumab, Dexamethasone, Ofatumumab, Revlimid, Arzerra, Revlimid, Arzerra | University of Liverpool, Royal Liverpool and Broadgreen University Hospital NHS Trust | Chronic lymphocytic leukaemia / Small Lymphocytic Lymphoma | | | | |
NCT02420210: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma |
|
|
| Terminated | 2 | 2 | US | Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Dexamethasone, DM, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis | University of Chicago, National Cancer Institute (NCI) | Diffuse Large B-Cell Lymphoma | 08/16 | 08/16 | | |
NCT01133743: Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 31 | Canada | Lenalidomide and Dexamethasone, Lenalidomide, Immunomodulatory drug(IMiD™), Thalidomide analogues | University Health Network, Toronto, Celgene Corporation | Chronic Lymphocytic Leukemia | 12/16 | 12/16 | | |
NCT02276248: Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma |
|
|
| Completed | 2 | 40 | RoW | Intensity-modulated radiation therapy, GDP chemotherapy | Chinese Academy of Medical Sciences | Stage I/II Extranodal NK/T-cell Lymphoma | 12/16 | 12/16 | | |
NCT02424045: Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma |
|
|
| Completed | 2 | 30 | NA | BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone), BCD chemotherapy | Samsung Medical Center | T-cell Lymphoma | 09/17 | 09/17 | | |
| Terminated | 2 | 14 | Europe, US, RoW | Isatuximab SAR650984, dexamethasone, acetaminophen, ranitidine, diphenhydramine | Sanofi, Sanofi-aventis recherche & développement | T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia | 11/17 | 11/17 | | |
| Unknown status | 2 | 88 | Europe | Rituximab, Temsirolimus, DHAP, intravenous, Temsirolimus-R-DHAP, Torisel, MabThera, Fortecortin, ARA-C, ARA-cell, Depocyte, R-DHAP, Rituximab-DHAP, Temsirolimus,Rituximab,Dexamethasone,Cisplatine,Cytarabine, Temsirolimus-Rituximab-DHAP | Mathias Witzens-Harig, Johannes Gutenberg University Mainz, Technische Universität München, Ludwig-Maximilians - University of Munich, University Hospital Ulm, University Hospital Erlangen, Charite University, Berlin, Germany, University Hospital Freiburg, Johann Wolfgang Goethe University Hospital | Diffuse Large B-Cell Lymphoma | 06/18 | 07/18 | | |
| Active, not recruiting | 2 | 86 | Europe | Obinutuzumab, GA, GA101, Dexamethasone, Aracytine, Cytarabine, Cisplatinum, Etoposide, Melphalan, Carmustine, BiCNU, BCNU | The Lymphoma Academic Research Organisation | Mantle Cell Lymphoma | 03/19 | 03/25 | | |
|
| Completed | 2 | 20 | RoW | HD-MTX-Ara-C regimen, high-does metrotrexate and cytarabine, FTD regimen, fotemustine, temozolomide and dexamethasone | Mingzhi Zhang, Zhengzhou University | Primary CNS Lymphoma (PCNSL) | 03/19 | 03/19 | | |
2018-000540-25: Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Terapia di salvataggio ( Carfilzomib + Lenalidomide +Desametasone) per linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK |
|
|
| Not yet recruiting | 2 | 59 | Europe | REVLIMID/LENALIDOMIDE, KRYPOLIS, [IMP1 - 5 MG], [IMP2], [IMP3- 10 MG], [IMP4 - 25 MG], Capsule, hard, Powder for solution for infusion, REVLIMID, KYPROLIS, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE | FONDAZIONE ITALIANA LINFOMI ONLUS, CELGENE, AMGEN | BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Unknown status | 2 | 62 | Europe | Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A. | Diffuse Large B-Cell Lymphoma | 09/20 | 09/20 | | |
NCT02955823: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL |
|
|
| Completed | 2 | 68 | Europe | Rituximab-Dexamethasone-Lenalidomide | Fondazione Italiana Linfomi ONLUS | Diffuse Large B-cells Non-Hodgkin Lymphoma | 09/20 | 11/22 | | |
| Unknown status | 2 | 15 | RoW | Bortezomib, Thalidomide, Dexamethasone | Seoul National University Hospital, Seoul National University Bundang Hospital | Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | 12/20 | 12/20 | | |
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL |
|
|
| Active, not recruiting | 2 | 16 | Europe | Carfilzomib, Lenalidomide, Dexamethasone | Fondazione Italiana Linfomi ONLUS | Mantle Cell Lymphoma | 12/20 | 12/22 | | |
NCT03154918: GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma |
|
|
| Unknown status | 2 | 60 | RoW | GLIDE, gemcitabine,Peg-ASP,ifosfamide,dexamethasone and etoposide | Sichuan University | Lymphoma, Extranodal NK-T-Cell | 12/20 | 03/21 | | |
ChiCTR-OIC-17013701: Phase II study of concurrent Chemoradiotherapy followed by Peg-Asp-IDE(PIDE) for localized Nasal Natural Killer/T-Cell Lymphoma: a prospective single-center clinical trial |
|
|
| Recruiting | 2 | 30 | | concurrent chemoradiotherapy followed by long-acting aspargase (pegylated aspargase, PEG-ASP) combined with Ifosfamide,dexamethasone and Etoposide (PIDE) treatment | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing | Natural Killer/T-Cell Lymphoma | | | | |
NCT02840539: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma |
|
|
| Completed | 2 | 19 | RoW | Bortezomib, Cytarabine, Dexamethasone, Pegteograstim, Protezomib, Cytarabine, Dexamethasone, Neulapeg | Seoul National University Hospital, Consortium for Improving Survival of Lymphoma | Mantle Cell Lymphoma | 03/21 | 12/22 | | |
| Recruiting | 2 | 15 | RoW | Gemcitabine, Pegaspargase, Etoposide, Dexamethasone | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma | 06/21 | 08/21 | | |
VIDL+ASCT, NCT02544425: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma |
|
|
| Recruiting | 2 | 27 | RoW | Etoposide, VP-16, Ifosfamide, Dexamethasone, L-asparaginase, Busulfan, Melphalan | Samsung Medical Center | Extranodal NK-T-Cell Lymphoma | 08/21 | 11/21 | | |
NCT04251065: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH |
|
|
| Active, not recruiting | 2 | 8 | Europe | Daratumumab, Darzalex | Fondazione Italiana Linfomi ONLUS | Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | 12/21 | 11/22 | | |
2021-002630-17: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine andDexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patientsHodgkin resistant to treatment of 1 line. |
|
|
| Not yet recruiting | 2 | 84 | Europe | Nivolumab, Concentrate for solution for infusion, OPDIVO | Medical Unicersity of Gdansk, Medical Research Agency | Refractory / relapsed Hodgkin's lymphoma Oporny/nawrotowy chłoniak Hodgkina, Refractory / relapsed Hodgkin's lymphoma, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800018710: Gemcitabine, Nab-paclitaxel, and Dexamethasone in Patients With Recurrent/refractory peripheral T cell lymphoma |
|
|
| Recruiting | 2 | 80 | | Receive Gemcitabine, Nab-paclitaxel, and Dexamethasone(GAD) chemotherapy | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, The foundation of 5010 Clinical Trials of Sun Yat-sen University | peripheral T cell lymphoma | | | | |
Nivo-DHAP, NCT04091490: Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
|
|
| Completed | 2 | 40 | RoW | Nivolumab, Opdivo | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Hodgkin Lymphoma | 12/22 | 12/22 | | |
NCT04405375: GPED Regimen for Relapsed/Refractory or Advanced ENKTCL |
|
|
| Recruiting | 2 | 29 | RoW | gemcitabin, Pegaspargase, Etoposide, Dexamethasone | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma, Nasal Type | 04/23 | 04/23 | | |
NCT04463953: Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia |
|
|
| Recruiting | 2 | 55 | RoW | Zanubrutinib,Ixazomib and Dexamethasone | Institute of Hematology & Blood Diseases Hospital | Waldenström Macroglobulinemia | 05/23 | 05/25 | | |
BURGUND, NCT03615664: The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD |
|
|
| Active, not recruiting | 2 | 115 | Europe | Bendamustine, Treanda, Gemcitabine, Gemzar, Dexamethasone, PET/CT, Autologous Stem Cell Transplant, ASCT | Polish Lymphoma Research Group | Hodgkin's Lymphoma | 06/24 | 09/24 | | |
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma |
|
|
| Recruiting | 2 | 320 | Canada | Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor | Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc | Lymphoma | 12/25 | 12/26 | | |
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 06/24 | 06/24 | | |
NCT05243693: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | Brentuximab vedotin, Adcetris | National Cancer Center, Korea | Relapsed/Refractory Classical Hodgkin Lymphoma | 02/24 | 03/26 | | |
NCT05774028: Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 50 | NA | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen | The First Affiliated Hospital with Nanjing Medical University | NK-T-Cell Lymphoma, Extranodal | 04/24 | 04/25 | | |
NCT05852717: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 32 | US | AutoSCT OR CAR T-cell Therapy, Autologous transplant, chimeric antigen receptor (CAR) T-cell, GDP, Epcoritamab | Dipenkumar Modi, Genmab | Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer | 06/24 | 06/25 | | |
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 84 | Canada | Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab | Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc. | Hodgkin Lymphoma | 06/25 | 06/26 | | |
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax | Institute of Hematology & Blood Diseases Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12/24 | 12/27 | | |
NCT02396043: Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | induction phase1, Vincristine,Pirarubicin,Prednisone,Pegaspargase, induction phase2, Cyclophosphamide,Cytarabine,Mercaptopurine, protocol M, Methotrexate,Mercaptopurine, maintenance therapy, 6-mercaptopurine,Methotrexate, reinduction phase1, reinduction phase2, Intrathecal (IT), methotrexate ,cytarabine and dexamethasone | Sun Yat-sen University | Lymphoma, Lymphoblastic | 03/25 | 03/25 | | |
19-C-0103, NCT03964090: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) |
|
|
| Active, not recruiting | 2 | 48 | US | TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate | National Cancer Institute (NCI) | Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | 07/25 | 07/26 | | |
| Recruiting | 2 | 80 | Europe | Mosunetuzumab, Dexamethasone | Oslo University Hospital, Hoffmann-La Roche, Aarhus University Hospital | Lymphoma, Follicular | 06/27 | 08/28 | | |
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 44 | US | Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF | UNC Lineberger Comprehensive Cancer Center, Genentech, Inc. | Diffuse Large B-cell Lymphoma | 08/28 | 08/28 | | |
NCT00531284: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma |
|
|
| Completed | 1b/2 | 184 | US | Carfilzomib, Kyprolis, Dexamethasone | Amgen | Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma | 10/14 | 05/17 | | |
|
|
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. |
|
|
| Withdrawn | 1b/2 | 156 | US | Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg | Epizyme, Inc. | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | 07/23 | 07/23 | | |
|
NCT01236586: RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia |
|
|
| Withdrawn | 1/2 | 0 | US | RO4929097, Dexamethasone | National Cancer Institute (NCI) | Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma, Wilm's Tumor | 04/11 | 04/11 | | |
| Unknown status | 1/2 | 50 | Europe | Combination of dexamethasone, ofatumumab and bendamustine, Ofatumumab (HuMax-CD20; ARZERRA), Bendamustine (Treanda; Ribomustin) | Southern Europe New Drug Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Lymphoma, Mantle-Cell | 04/12 | 06/12 | | |
|
2010-021086-73: HD-R3i - A study to improve the treatment of relapsed or refractory Hodgkin Lymphoma Patients using additional RAD001 (everolimus) to DHAP-chemotherapy HD-R3i - Eine Studie zur Verbesserung der Behandlung von rezidiverten oder refraktären Hodgkin Lymphom Patienten mittels Zugabe von RAD001 (everolimus) zur DHAP-Chemotherapie |
|
|
| Ongoing | 1/2 | 73 | Europe | everolimus, Tablet, Solution for infusion, Afinitor 2,5mg, dexamethasone, Afinitor 5,0mg | University of Cologne, Novartis Pharma GmbH | relapsed or refractory Hodgkin Lymphoma rezidiviertes oder refraktäres Hodgkin Lymphom, reappearance of Hodgkin Lymphoma or Hodgkin Lymphoma that did not respond to therapy Rückfall eines Hodgkin Lymphoms oder Hodgkin Lymphom, das auf Therapie nicht ansprach, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 1/2 | 20 | Europe | Vorinostat, Lenalidomide, Revlimid®, Zolinza® | Arbeitsgemeinschaft medikamentoese Tumortherapie, Merck Sharp & Dohme LLC, Celgene Corporation | Peripheral T-Cell Non-Hodgkin's Lymphoma | 07/12 | 07/12 | | |
| Terminated | 1/2 | 34 | Europe | Rituximab, MabThera, Cisplatin, Cisplatinum, Carboplatin, Carboplatinum, Dexamethasone, Cytarabine, Cytarabin, Ara-C, Lenalidomide, Revlimid, PegFilgrastim, Neulasta, peripheral stem cell collection, peripheral stem cell apheresis, hematopoetic stem cell apheresis, peripheral hematopoetic stem cell apheresis | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, Celgene, Amgen | Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL), Aggressive Marginal Zone Lymphoma (MZL) | 01/14 | 04/15 | | |
2013-002711-94: HOVON 124 WM study: A trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia. |
|
|
| Ongoing | 1/2 | 72 | Europe | MLN9708 4 mg, rituximab, MLN9708 3 mg, MLN9708 2,3 mg, Capsule, hard, Concentrate for solution for infusion, Solution for injection, Mabthera 100mg/10ml, Mabthera 500mg/50ml, Mabthera s.c. | HOVON Foundation, Dutch Cancer Society, Millennium, Roche Nederland BV, Roche Belgium, Roche (Hellas) S.A. | Waldenström's macroglobulinemia, Morbus Waldenström, Diseases [C] - Cancer [C04] | | | | |
NCT01389427: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). |
|
|
| Completed | 1/2 | 41 | Europe | Torisel dose 15 mg and R-CHOP, Arm A cohort -1, Torisel dose 15 mg and R-FC, Arm B cohort -1, Torisel dose 15 mg and R-DHA, Arm C cohort -1, Torisel dose 25 mg and R-CHOP, Arm A cohort 1, Torisel dose 50 mg and R-CHOP, Arm A cohort 2, Torisel dose 75 mg and R-CHOP, Arm A cohort 3, Torisel dose 25 mg and R-FC, Arm B cohort 1, Torisel dose 50 mg and R-FC, Arm B cohort 2, Torisel dose 75 mg and R-FC, Arm B cohort 3, Torisel dose 25 mg and R-DHA, Arm C cohort 1, Torisel dose 50 mg and R-DHA, Arm C cohort 2, Torisel 75 mg and R-DHA, Arm C cohort 3 | The Lymphoma Academic Research Organisation, French Innovative Leukemia Organisation | Mantle Cell Lymphoma Refractory | 05/15 | 09/15 | | |
| Completed | 1/2 | 92 | Europe | Notch II Inhibitor, Dexamethasone, LY3039478, Capsule, hard, Tablet, Dexamethason - Jenapharm, Dexa-CT, Dexa-Hexal | Eli Lilly and Company, Eli Lilly and Company | T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL), Leukemia and Lymphoma or blood cancer, Diseases [C] - Cancer [C04] | | | | |
| Unknown status | 1/2 | 72 | Europe | DHAP, Dexamethasone, AraC, Cisplatin, Brentuximab Vedotin, Adcetris, SGN-35, Autologous Peripheral Blood Stem Cell Transplantation, ASCT | Marjolein Spiering, Millennium: The Takeda Oncology Company | Hodgkin Lymphoma, Refractory, Relapse | 11/18 | 05/20 | | |
|
NCT01084252 / 2013-001418-13: Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies |
|
|
| Completed | 1/2 | 351 | Europe, US, RoW | Isatuximab SAR650984, Sarclisa, Dexamethasone | Sanofi | Hematological Malignancy | 12/18 | 07/23 | | |
|
|
| Completed | 1/2 | 307 | Europe, Canada, US, RoW | Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone | Kite, A Gilead Company | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL) | 07/23 | 07/23 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 1/2 | 316 | Europe, US | Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, BMS-734016, MDX010, Lirilumab, BMS-986015, Daratumumab, Darzalex, Pomalidomide, Pomalyst, Dexamethasone, Intensol | Bristol-Myers Squibb, Janssen, LP | Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma | 09/20 | 12/23 | | |
|
|
|
|
|
|
NCT03246750: B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma |
|
|
| Completed | 1/2 | 34 | RoW | B-MAD chemotherapy, Involved field radation, cisplatin | The Thai Lymphoma Study Group, Takeda | Extranodal NK/T-cell Lymphoma | 04/24 | 04/24 | | |
NCT04756726: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma |
|
|
| Recruiting | 1/2 | 158 | US | CFT7455, Dexamethasone Oral | C4 Therapeutics, Inc. | Multiple Myeloma, Lymphoma, Non-Hodgkin's | 09/25 | 12/25 | | |
NCT05441761: Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL |
|
|
| Recruiting | 1/2 | 60 | RoW | liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Treatment, Peripheral T-cell Lymphoma | 05/25 | 05/25 | | |
NCT03114865: A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance |
|
|
| Active, not recruiting | 1/2 | 44 | US | Blinatumomab 9ug, Blincyto, Blinatumomab 28 ug, Blinatumomab, Dexamethasone | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Amgen | Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 250 | Europe, US | CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax | CellCentric Ltd. | Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 662 | Europe, US, RoW | rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | 03/29 | 03/29 | | |
|
|
|
|
|
|
HEM-iSMART B, NCT05751044: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies |
|
|
| Not yet recruiting | 1/2 | 26 | Europe | Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine, intrathecal chemotherapy | Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | 10/31 | 10/31 | | |
